Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Glioblastoma 154 Brain Neoplasms 73 Glioma 69 Central Nervous System Neoplasms 50 Gliosarcoma 46 Astrocytoma 37 Melanoma 36 Oligodendroglioma 29 Neuroblastoma 17 Neoplasm Metastasis 14 Carcinoma, Non-Small-Cell Lung 12 Lung Neoplasms 11 Sarcoma, Ewing 10 Sarcoma 10 Neoplasms 10 Medulloblastoma 10 Recurrence 9 Neuroendocrine Tumors 9 Lymphoma 8 Ependymoma 8 Breast Neoplasms 8 Small Cell Lung Carcinoma 7 Rhabdomyosarcoma 7 Diffuse Intrinsic Pontine Glioma 7 Colorectal Neoplasms 7 Carcinoma, Neuroendocrine 6 Adenoma, Islet Cell 6 Uveal Melanoma 5 Spinal Cord Neoplasms 5 Pheochromocytoma 5

Interventions

Prednisone 3 pembrolizumab 2 Melphalan 2 Cytarabine 2 venetoclax 1 ofatumumab 1 obinutuzumab 1 ioflupane 1 imetelstat 1 ibrutinib 1 gossypol acetic acid 1 gilteritinib 1 fluorocholine 1 fluciclovine F-18 1 deltacortene 1 daratumumab 1 aflibercept 1 abiraterone 1 Temozolomide 1 Self-Management 1 Quality of Life 1 Professional Autonomy 1 Paclitaxel 1 Oncolytic Virotherapy 1 Octreotide 1 Mitoxantrone 1 Methylene Blue 1 Lenalidomide 1 Gemtuzumab 1 Gemcitabine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Disease × Temozolomide × Clear all

NCT00660283 2010-01-20

KARE003

Kentuckiana Cancer Institute

Phase 2 Unknown

Disease, Glioma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡